A drug used to treat non-small cell lung cancer that has spread to other parts of the body. It is used in patients whose cancer has a mutated (changed) form of a cell protein called epidermal growth factor receptor and whose disease got worse during or after treatment with an anticancer drug that blocks EGFR. It is also being studied in the treatment of other types of cancer. Tagrisso blocks this mutated protein, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor. Also called osimertinib.